1. Generics Bulletin
  2. >>Business

ANI Revises Its Expectations Up Following Record Revenues

Analysts Conservative About Company Future Despite Banner Performance

 
• By Chloe Kent

ANI has revised up its annual expectations in the face of an outstanding first quarter, which saw it beat market expectations by a substantial margin.

Bar chart with ascending columns ridden by a man on a red bull
ANI has raised its revenue guidance by approximately 26% • Source: Shutterstock

ANI Pharmaceuticals, Inc. has revised up its full-year guidance for 2023 following a record quarter, as the firm’s pivotal Cortrophin gel (repository corticotropin injection) 80 U/ml launch and scale-up of its generics business – boosted by competitor supply disruption during Q1 – continue to propel the firm forward.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.